Executive Summary
 Investigation of mechanisms governing development and normal and abnormal function of the human central nervous system (CNS) is hampered by its complexity and the very limited possibility of experimentally manipulating it in-vivo.
 Development of 3-dimensional (3D), tissue-like culture systems offers much promise for boosting our understanding of human neural development, birth defects, neurodegenerative diseases and neural injury  3D models of the human CNS can provide platforms that will allow us to more accurately predict efficacy of putative therapeutic compounds and assess responses to potentially neurotoxic agents.
 Novel technological developments and a more interdisciplinary approach to modelling the human CNS underpin development of these model  As we increase the complexity of in-vitro systems to make them more tissue-like, the challenge of establishing highly reproducible models amenable to quantitative and high throughput analysis also increases.
Article
The central nervous system (CNS) neuron has about 5000-200,000 synapses [1] . Finely tuned interactions between all different cell types through both physical and biochemical mechanisms lead to a highly sensitive and well-regulated environment [2] . The complexity of the human brain together with the limited possibility of experimentally manipulating it in vivo, however, poses major challenges to study mechanisms governing human neural development, neurodegenerative diseases and responses to injury at the cellular and molecular level. The results of animal studies, though of crucial importance to provide insights in some of these mechanisms, cannot be simply extrapolated to humans. Rodents have reduced cognition, less complex brain structure and transgenic animal models of neural diseases often lack features of the pathological phenotype observed in humans; examples of human neurological diseases that are challenging to model in animals include amyotrophic lateral sclerosis (ALS), Huntington disease and Parkinson disease and autism [3] [4] [5] [6] [7] [8] . Furthermore, some of the species that might better recapitulate certain human neurological diseases are not traditional laboratory animals; hence, in addition to ethical issues and the high cost involved working with these models, there is a lack of suitable reagents available for their effective in depth study [4, 5, 9] . There are some significant differences between humans and rodents also at the cellular and molecular level; for example, rodent cells have longer telomeres that can account for differences in the severity of disease phenotype as compared to humans, and can respond differently to growth factors, cytokines and several toxic agents [10] [11] [12] [13] [14] [15] .
Hence it is not all that surprising that many CNS-targeted therapeutics that offer much promise in animal models of neural diseases fail in clinical trials. A key challenge is to develop tools to bridge this gap in order to improve our understanding of healthy and diseased human CNS at the cellular and molecular levels, and better predict efficacy of novel therapeutic strategies in humans. [16] . Because of the obvious ethical constraints, this has to be achieved by modelling the human CNS in vitro.
"Old" and" new" cell sources for human neural tissue modelling
In vitro models, that have largely been 2-dimensional (2D, monolayers), significantly reduce the complexity of the whole organism into a more defined and controlled system, allow easy manipulation of both cells and their environment and thus allow us to study phenomena that cannot be observed or measured in vivo.
Because of the limited availability of human tissue and the need for large quantities of material, especially for biochemical and pharmacological studies, human neural cell lines have been much used in neuroscience. Many commonly used human cell lines were derived from naturally occurring tumours such as astrocytomas (e.g.U-87, U-251), oligodendrogliomas (e.g. HOG), ependymomas, glioblastomas, and primitive neuroectodermal tumors (e.g. TERA-2 and its subclone, the NT-2 line) [17] . Neuroblastomas, child solid tumours composed of neural crest derived precursors of the sympathetic nervous system, have been also extensively used as an easily available source of neuronal-like cells (e.g. SH-SY5Y) as following differentiation they display many feature of dopaminergic neurons [18] . In general, transformed human neural lines maintain some of the properties of native cells; therefore, as long as these models'
limitations are taken into account, they can provide useful tools particularly for cellular and molecular studies (e.g. investigation of signalling pathways).
The use of non-tumor-derived human neural cells has significantly gained momentum over the last couple of decades following the discovery of neural stem cell presence not only in the developing CNS but also postnatally, and the development of strategies for their isolation, long-term culture and differentiation into neurones and glia (astrocytes and oligodendrocytes).
This has gone hand in hand with developing protocols to generate different neural cell types from pluripotent human embryonic stem cells (ESCs [23] . Significantly, the number of open-access repositories of cells from patients carrying a variety of diseases is also rapidly increasing, with some focusing on neural diseases, but more are needed [24, 25] . It will be crucial to ensure long-term funding for maintenance and expansion of these important resources and guarantee their availability to the wider scientific community.
An example of how an iPSC-based model can be relevant to studying a disease and for therapeutic development is that of amyotrophic lateral sclerosis (ALS). This fatal disease is caused by mutations in superoxide dismutase 1 (SOD1) that lead to spinal neurone loss with consequent muscle wasting and paralysis. Currently, the only drug available to ALS patients merely delays the onset of some disease traits. The discovery of new drugs for ALS has been hampered by the lack of suitable models for preclinical testing as rodent models do not entirely mimic the human disease phenotype [3, 5] . Neurones from ALS patient-derived iPSCs were found to display disease characteristics and have provided valuable insights into the activity of different drugs [25] .
Moving towards neural tissue-like structures
Together, iPSCs provide a unique tool for studying human neural diseases for which there are no transgenic animal models fully reproducing the disease phenotype [16] . However, they have so far been mainly used in 2D cultures. While such cultures allow easy expansion, monitoring, and manipulation of cells, they also impose highly unnatural constraints on the cells. Cell behaviour, morphology and gene expression under these conditions can differ significantly from those observed in vivo. In addition, cells grown as monolayers often appear to be more susceptible to drugs and therapeutic agents ( [26] [27] [28] and our paper in preparation). With increasing awareness of the importance of the environmental context for cell physiology, interest is growing in developing more complex cell culture systems that better reflect the situation in vivo and thus allow the cells to behave in a physiologically more relevant manner.
To achieve this goal key properties of tissues need to be reproduced as closely as possible in the in vitro models (Figure 1 ).
Development of three-dimensional (3D) human culture models can bridge the gap between native tissue and monolayer cell culture systems and increase the relevance of in vitro studies.
A 3D architecture reduces the strain and artificial responses cells undergo to adapt to a flat surface as it allows them to spread and interact with adjacent cells in all dimensions. This results in different modulation of microenvironmental cues such as cell-cell and cell-matrix interactions, mechanical forces and diffusible factors providing a more natural environment that supports formation of a tissue-like architecture and can allow tackling questions that cannot be addressed in 2D systems [29, 30] . For example, modelling human CNS traumatic injuries using compressive impacts could not be achieved in 2D cultures [31] .
The idea that 3D is better than 2D is not new. Nevertheless, as discussed above, if we are to model neural diseases, either patient-derived iPSCs, or ESCs or neural stem cells modified to carry the defective disease causing gene need to be used, and conditions that will give rise to a neural-like tissue in culture established.
The 3D model of choice, the complexity one aims to achieve and the strategy to be used to build it will depend on the specific questions to be addressed using that model. For example, when models are needed for studying mechanisms of human CNS development and disease, it can be acceptable to use systems that will slowly become organised into neural-like tissues and use quite complex and relatively time-consuming analytical approaches. In contrast, if a system is to be used for initial drug screening, it needs to be relatively easy to handle, inexpensive, highly reproducible, and able to provide clear readouts with medium to high throughput.
Although the notion of bottom-up and top-down approaches is more commonly used in the context of tissue engineering, these approaches, either alone or in combination, can also be broadly applied to the construction of neural models [16] .
In the bottom-up approach a model is put together from individual components to give rise to a more complex system. With this approach, cellular (e.g., phenotypes, ratios, densities)
scaffold parameters (controlling mechanical properties and bioactive motifs) and construction approach (e.g. bioprinting) are defined to design and build the model in as controlled fashion as possible. They usually involve the use of a scaffold, and the type of scaffold selected depends on the desired characteristics and functionality of the 3D culture and on the method chosen to "build the tissue". For example, a relatively simple 3D model involves the use of rigid polystyrene scaffolds where human NSCs can be grown and induced to differentiate into mature neurons that form active and functional neuronal networks [35] . Hydrogels rich in brain extracellular matrix proteins, such as Matrigel, are extensively used to "glue" cells together in a 3D environment; as these scaffolds are not rigid, they allow for remodelling and are used also for top-down modelling. To give an example, Matrigel-embedded human NSCs overexpressing mutated human β-amyloid precursor protein and presenilin 1 have been used to establish a model of Alzheimer's disease. Upon induction of neuronal differentiation, these cells successfully recapitulated amyloid-β and tau pathology with robust extracellular deposition of amyloid-β plaques [36] . This model of Alzheimer's disease, as well models of other human neurodegenerative disorders developed using a similar strategy, will be valuable both for better understanding disease mechanisms and for therapeutics development.
The bottom-up approach could also allow generation of neural tissue of greater complexity by modular and patterned inclusion in the selected scaffold of different cell types (e.g. neurones, astrocytes, oligodendrocytes, microglia and endothelial cells) to interrogate their roles and interactions in biological processes. For example, it is difficult to study myelination and interactions between oligodendrocytes, the myelin-forming cells in the CNS, and neurons in the human developing brain, as it is currently hard to achieve efficient differentiation of hNSCs into oligodendrocytes and significant myelination in vitro. This is a bit of a vicious circle and highlights the inadequacy of the models used, as much information on the mechanisms regulating this process in the human brain is still missing, and myelination is a very "spatial"
process that requires a 3D system. It is becoming apparent from animal studies that the developmental age of the oligodendrocytes and the presence of astrocytes may be key to efficient myelination [37] . This could be tested by systematically building human 3D models [49] , and stratified retinas [42, [46] [47] [48] 50] . A limiting factor for successful long-term maintenance and maturation of organoids is nutrient availability. By using a spinning bioreactor to enhance nutrient absorption, ESCs in Matrigel droplets can be maintained in culture for months (up to 10 months), allowing formation of brain organoids containing discrete regions that resemble cerebral cortex, ventral telencephalon, choroid plexus, retina and meninges [45] . The same approach was used to generate brain organoids from microcephaly patient-specific iPSCs to model this neurodevelopmental disorder in vitro [45] .
The use of iPSC-derived neural organoids is rapidly expanding, and they have been recently used to study autism spectrum disorder, to model the effect of Zika virus infection, and to investigate evolutionary mechanisms underlying expansion of the human cortex, just to give some examples [46] [47] [48] .
Challenges ahead
Notwithstanding all these exciting developments, establishment of highly reproducible 3D neural models is still in its infancy and presents several challenges (Figure 2 ). First of all the brain tissue has very high cellularity with little ECM. The average cell density in the brain is thought to exceed 100,000 cells/μL. Cell density has been shown to influence cell behaviour, including survival and differentiation [2] . Most culture systems cannot accurately reproduce this high cell density that is usually an order of magnitude lower than that found in vivo [51] .
As already mentioned, high cellular densities raise the issue of adequate nutrient supply.
Passive diffusion of nutrients and gasses is not sufficient to meet the metabolic demands of these dense cultures and further development of bioreactors providing continuous medium perfusion will be necessary [52] . Another approach to address these difficulties is miniaturization of the whole system using microfluidic devices [46] . [16, 35, 58] .
Together, future development of reproducible and cost-effective human 3D models suitable for assessing mechanisms of neural development and disease, efficacy of therapeutic agents, or toxic responses, will require an extensive and well-integrated multidisciplinary effort [59, 60] .
Although further refinement of 3D neural culture systems is much needed, it is already apparent that this in vitro approach can provide more tissue-like and physiologically relevant models for the study of the healthy and diseased human CNS, and help to increase accuracy in the evaluation of potential therapeutics, while reducing the need for animal studies.
Finally, the availability of physiologically relevant 3D neural culture models, together with a better understanding of neural disease mechanisms and identification of novel neural tissuecompatible scaffolds, might aid development of a diverse range of therapeutic approaches. For example, it could provide valuable references for the development and testing of novel matrices that can fill brain cavities following traumatic injury or stroke and be cellularised by endogenous cells [61] [62] [63] [64] , or aid devising cell-based systems for the delivery of neuroprotective factors in diseased brains [65] .
Future Perspective
Development of human neural disease 3D models is taking momentum. It is anticipated that over the next few years interdisciplinary effort between biologists, physiologists, engineers and material scientists will accelerate establishment of reproducible human CNS models in vitro and will support more automated analysis of cellular, molecular and physiological responses.
Such effort will provide a range of novel platforms that will be valuable both for understanding human disease mechanisms and for performing initial medium/high throughput screenings of neuroactive compounds with increased power for predicting therapeutic potential, as well as neurotoxic effects, in humans. The advantages of this approach will not only be a significant reduction in the use of animals at the early stages of the drug discovery process, or in developmental neurotoxicology studies, but also a more in depth knowledge of the human disease mechanisms and a better understanding of interspecies differences. This in turn will help to develop/select better animal models for subsequent in vivo studies that are mandatory prior to clinical trials, that will underpin a more accurate interpretation of the results, hence reducing the risk of failure at advanced stages of therapeutic development. and nuclei (blue).
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